Charles-André Brouwers

Senior Partner and Managing Director,

Boston Consulting Group

Wed., February 16 | Noon

Sustainability of the US Generic Model

The generic and biosimilar pharmaceutical sector plays a central role in the U.S. health care system. Intensifying competition and price pressure are challenging the traditional generic business model. Can companies continue to operate as they do today, or will their business models have to change? How will this impact the overall healthcare system?

Join Charles-André Brouwers, the head of Boston Consulting Group’s Generics Practice, as he addresses these and other critical questions for the generic industry.

Charles-André Brouwers is a Managing Director & Senior Partner in BCG’s New York office. In the course of his 28 years, he’s developed a deep knowledge of the biopharma industry through serving clients in Europe, the USA and Asia.

Charles-Andre founded and leads BCG’s generic team. He has extensive experience in maximizing the value of assets post lost of exclusivity including in the context of:

• Generic defense
• Generic portfolio maximization
• Branded generics
• Hard-to-make generics
• OTC switches
• Differentiated generics (505b2)

His experience also includes work in consumer driven segments such as OTC or contact lenses; and the development of launch and commercial strategies for new innovative product (diabetes, CNS, oncology).

Mr. Brouwers was previously Vice President and head of the Life Science division of Cap Gemini and successively led in France/Benelux, the USA and globally. Mr. Brouwers holds an MBA from Carnegie-Mellon University and a Masters in Electronic Engineering from the University of Liege, Belgium.